Presentations and Interviews

 PresentationMediaDate
The Presentation on the NeuroRestore ACD856 publication: “Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer’s Disease” by Pontus Forsell et al from 2024, published in Pharmaceuticals (2024; 17(8), 997 December 20, 2024
CEO, Martin Jönsson at Redeye Theme Event Neurology December 3, 2024
AlzeCure's CEO Martin Jönsson presented at Aktiespararnas Stora Aktiedagarna in Stockholm (Swedish) November 27, 2024
CEO Martin Jönsson at Finwire - About the progress and in the future in Alzheimer's and pain. (Swedish) November 11, 2024
Poster from Ctad 2024 - Preclinical evidence for anti-inflammatory and immunomodulatory effects of NeuroRestore ACD856, a Trk-PAM in clinical development for the treatment of Alzheimer’s disease October 29, 2024
CEO, Martin Jönsson to presented at Redeye’s Neurology Day, Presentation about AlzeCure, our Alzheimer and pain platforms, projects, etc. October 23, 2024
ACD440 – A novel non-opioid analgesic – From AlzeCures live-event. October 23, 2024
ACD440 – A novel non-opioid analgesic, with Dr. Rolf Karlsten - AlzeCure´s live event. October 23, 2024
ACD440 – A novel non-opioid analgesic, with Märta Segerdahl, CMO and project manager - AlzeCure´s live event. October 23, 2024
Presentation about AlzeCure by CEO Martin Jönsson, presented at LSX Nordic Congress October 8, 2024
Interview with CEO Martin Jönsson and CSO Johan Sandin at Redeye about the ACD856 poster on an anti-inflammatory effect to be presented at CTAD, October 1, 2024 (Swedish) October 1, 2024
AlzeCures CEO, Martin Jönsson at Finwire (Swedish ) August 27, 2024
Watch the latest interview at Redeye with our CEO, Martin Jönsson (Swedish) August 20, 2024
Alzecure’s pain project TrkA-NAM presented at the pain conference IASP, Augusti 5-9 2024 – Pharmalogical Effects of ACD137, a Potent and Selective Negative Allosteric Modulator of TrkA August 7, 2024
CEO Martin Jönsson presents at Redeye Investor forum (Swedish) May 16, 2024
Interview at Redeye with CEO, Martin Jönsson (Swedish) May 6, 2024
SITDOWN at Finwire - AlzeCures CEO, Martin Jönsson about the rights issue (Swedish) May 2, 2024
Interview at Finwire with Johan Sandin, CSO (Swedish) May 2, 2024
Rights issue presentation with CEO Martin Jönsson (Swedish) May 2, 2024
AlzeCure's CEO Martin Jönsson at Redeye (Swedish) April 11, 2024
CEO Martin Jönsson presenting at Finwire (Swedish) April 10, 2024
AlzeCure's CEO Martin Jönsson at Redeye's event on Alzheimer's (Swedish) March 21, 2024
AlzeCure presents new preclinical data with NeuroRestore ACD856 at leading Alzheimer’s conference, AD/PD 2024 March 7, 2024
Expert Event - Advances in the treatment of Alzheimer’s disease – Small molecule Gamma-Secretase Modulators (GSMs) as promising disease-modifying treatments together February 19, 2024
Alzheimer’s disease and the amyloid hypothesis – Professor Henrik Zetterberg, MD, PhD, Gothenburg University & University College London, AlzeCure Pharma expert event February 19, 2024
Alzstatin: a small molecule disease modifying and preventive therapy against Alzheimer’s – Johan Sandin, PhD, CSO, AlzeCure; AlzeCure Pharma expert event with Johan Sandin, PhD, CSO, AlzeCure February 19, 2024
Welcome address, agenda & company overview, – Martin Jönsson, CEO, AlzeCure; AlzeCure Pharma expert event - Alzheimer’s around highly current gamma-secretase modulators February 19, 2024